AIS has been racking up some solid pr's of late...1.35 up .04---this today-
EXTON, Pa., Dec. 6 /PRNewswire-FirstCall/ -- Antares Pharma, Inc. (Amex: AIS) today announced having signed a development agreement with a presently unnamed pharmaceutical company specializing in products for the treatment of central nervous system (CNS) disorders. Under the agreement, Antares will apply its advanced transdermal delivery (ATD(TM)) gel platform to create a new, branded pharmaceutical product. Antares will recognize research and development revenue from this work, which is currently underway. Commercial terms have been agreed upon and will be included in a subsequent license agreement upon successful completion of the initial phase of this program. James Hattersley, Vice President of Corporate Business Development at Antares Pharma, said, "We look forward to designing an effective, patient- compliant prescription product with our partner based on Antares' proven ATD(TM) gel technology." Jack E. Stover, President and CEO of Antares Pharma, said, "This agreement represents another key application of our ATD(TM) platform further validating both the system and our overall product based strategy. Our ATD(TM) system offers compelling benefits to the patient in comparison to other drug delivery dosage forms, which we believe can differentiate and add significant value to a wide range of transdermally administered pharmaceutical products." Antares' patent-protected ATD(TM) gel technology platform has been clinically and commercially validated for the systemic delivery of a variety of compounds. In addition, the development of modified gel systems for non- systemic, dermal delivery has also been achieved. Load leveling of drug in the ATD(TM) platform may be the same or higher than in conventional transdermal systems, can be sustained for 24 hours after once daily application, and can be accurately delivered via a metered dose pump or a unit dose sachet packaging. The cosmetic quality is superior as ATD(TM) gels are both transparent and non-staining. Generally, there is very low irritation potential for our ATD(TM) gels as product formulations fully disappear within 2-3 minutes. More than one active compound may also be delivered simultaneously, each at a different concentration, such that the permeation profile of each agent is optimally maintained. About Antares Pharma Antares Pharma is a specialized pharma product development company with patented drug delivery systems and injectable device engineering capabilities. Antares' current technology platforms include its ATD(TM) Advanced Transdermal Delivery system, Easy Tec(TM) oral fast-melt technology, and subcutaneous injection technology platforms including both Vibex(TM) disposable mini-needle injection device and Valeo(TM)/Vision(R) reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares' product pipeline will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. Antares has active partnering programs with several pharmaceutical and distribution companies for a number of indications and applications, including diabetes, growth disorders, obesity, female sexual dysfunction and other hormone therapy. Its needle-free injector system is distributed in more than 30 countries for the administration of insulin and is marketed for use with human growth hormone through licensees in most major regions of the world. Licensees also market an ibuprofen gel in several major European countries. In addition, Antares Pharma is undertaking development or is conducting research on several product opportunities that it expects will form the basis of its specialized pharma program. Antares Pharma has corporate headquarters in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland. |
